MedDataX Logo

Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers

NCT ID: NCT00765427

Last Updated: 2009-03-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Healthy volunteer subjects will receive retinoid QLT091001 once-daily for 7 days for safety observation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Human Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QLT091001

7-day repeated dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects with ECG within normal limits and normal blood pressure and resting heart rate

Exclusion Criteria

* Subjects with any clinically important abnormal physical finding at screening.
* Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 60 days of baseline.
* Female subjects who are either pregnant or lactating.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

QLT Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

QLT Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Victor Lao, MD

Role: PRINCIPAL_INVESTIGATOR

Andrew Strong, Ph.D.

Role: STUDY_DIRECTOR

QLT Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RET HV 01

Identifier Type: -

Identifier Source: org_study_id